Progress and new standards of care in the management of HER-2 positive breast cancer
- 28 February 2007
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 43 (3), 497-509
- https://doi.org/10.1016/j.ejca.2006.10.020
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancerBreast Cancer Research and Treatment, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences of the United States of America, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogeneEuropean Journal Of Cancer, 2001
- EpirubicinDrugs, 1993
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987